Analysts See $-0.12 EPS for Novavax, Inc. (NVAX)

October 13, 2018 - By Louis Casey

Novavax, Inc. (NASDAQ:NVAX) LogoInvestors sentiment increased to 2.11 in Q2 2018. Its up 0.55, from 1.56 in 2018Q1. It is positive, as 16 investors sold Novavax, Inc. shares while 21 reduced holdings. 25 funds opened positions while 53 raised stakes. 160.47 million shares or 7.74% more from 148.94 million shares in 2018Q1 were reported.
Profund Advsrs Limited Com invested in 0% or 15,561 shares. Jpmorgan Chase And has invested 0% in Novavax, Inc. (NASDAQ:NVAX). Barclays Public Ltd Company has 53,871 shares. Voya Investment Mgmt Ltd Llc stated it has 152,002 shares. Public Employees Retirement Association Of Colorado accumulated 60,532 shares or 0% of the stock. Art Advsr Ltd Liability Com has 168,710 shares. Wellington Grp Inc Llp owns 1.41 million shares. Sg Americas Securities Limited Liability Com owns 102,003 shares or 0% of their US portfolio. Chicago Equity Ptnrs Lc holds 761,035 shares or 0.03% of its portfolio. Fisher Asset Mngmt Limited Co, Washington-based fund reported 143,965 shares. Fincl Architects Incorporated holds 0% or 1,500 shares in its portfolio. Ameritas Partners accumulated 32,730 shares. Credit Suisse Ag owns 862,338 shares for 0% of their portfolio. Royal Retail Bank Of Canada owns 41,909 shares. Balyasny Asset Mgmt Ltd Liability stated it has 493,820 shares.

Since May 14, 2018, it had 3 buys, and 0 sales for $208,866 activity. Shares for $164,620 were bought by Erck Stanley C.

Analysts expect Novavax, Inc. (NASDAQ:NVAX) to report $-0.12 EPS on November, 6.They anticipate $0.03 EPS change or 20.00 % from last quarter’s $-0.15 EPS. After having $-0.12 EPS previously, Novavax, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.14% or $0.06 during the last trading session, reaching $1.97. About 4.12 million shares traded. Novavax, Inc. (NASDAQ:NVAX) has risen 28.07% since October 14, 2017 and is uptrending. It has outperformed by 12.45% the S&P500.

Novavax, Inc. (NASDAQ:NVAX) Ratings Coverage

Among 2 analysts covering Novavax (NASDAQ:NVAX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Novavax had 2 analyst reports since May 17, 2018 according to SRatingsIntel. JP Morgan upgraded the stock to “Overweight” rating in Friday, September 21 report. The stock of Novavax, Inc. (NASDAQ:NVAX) has “Buy” rating given on Thursday, May 17 by FBR Capital.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $753.71 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

More notable recent Novavax, Inc. (NASDAQ:NVAX) news were published by: which released: “Here’s Why Novavax Gained 20.5% in September” on October 10, 2018, also with their article: “Novavax Shares Strengthen As A Key Catalyst Approaches” published on September 25, 2018, published: “ResVax, NanoFlu Prospects Earn Novavax A Double Upgrade” on September 21, 2018. More interesting news about Novavax, Inc. (NASDAQ:NVAX) were released by: and their article: “Novavax to Present at Two Upcoming Investor Conferences” published on September 26, 2018 as well as‘s news article titled: “FBR: Novavax Looks Healthy Ahead Of Catalysts” with publication date: October 08, 2018.

Novavax, Inc. (NASDAQ:NVAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News